Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Benefit of chemotherapy on survival in women aged ≥ 70 with HR-positive, HER2-negative breast cancer and N2-like nodal burden: A population-based analysis.

Noor Khalid, Mohammad Baraa Boozo, Waqas Azhar Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12703

e12703 Background: High-risk localized hormone receptor (HR)-positive, HER2-negative breast cancer is often treated with c...

Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma: Long-term follow-up of the GERCOR NEONIPIGA phase II study.

Thomas Samaille, Julie Henriques, David Tougeron et al. Jun 01, 2026 pp. 4099-4099 10.1200/jco.2026.44.16_suppl.4099

4099 Background: Neoadjuvant nivolumab and ipilimumab in localized MSI/dMMR gastric cancer were evaluated in the NEONIPIGA...

Time to treatment initiation for triple-negative breast cancer in Brazil: A call for public health action.

Fernanda Madasi Pinheiro, Renata Colombo Bonadio, Wesley Antônio Lopes de Lima et al. Jun 01, 2026 pp. 1544-1544 10.1200/jco.2026.44.16_suppl.1544

1544 Background: Timely initiation of treatment is a critical determinant of outcomes in breast cancer. In Brazil, nationa...

Multiomic spatial analysis of tumor microenvironment during neuroendocrine (NE) transformation in <i>EGFR</i> -mutant LUAD.

Elisa Gobbini, Darwin D'Souza, Emir Radkevich et al. Jun 01, 2026 pp. 8085-8085 10.1200/jco.2026.44.16_suppl.8085

8085 Background: Histological transformation of EGFR mutant lung cancer adenocarci...

daNIS-3: A phase II platform study of NIS793 and anti–PD-1 combined with standard of care (SoC) anti-cancer therapy for the second-line (2L) treatment (tx) of microsatellite-stable colorectal cancer (MSS CRC).

Filippo Pietrantonio, Iosune Baraibar, Jiri Tomasek et al. Jun 01, 2026 pp. 3529-3529 10.1200/jco.2026.44.16_suppl.3529

3529 Background: Despite advances in tx of MSS CRC including targeted tx, the prognosis remains poor. The daNIS-3 study (N...

Radiotherapy followed by systemic therapy and tislelizumab in microsatellite-stable rectal cancer with synchronous unresectable metastases: Updated results of the MIRACLE-2 study.

Menglong Zhou, Lijun Shen, Zezhi Shan et al. Jun 01, 2026 pp. 3578-3578 10.1200/jco.2026.44.16_suppl.3578

3578 Background: Microsatellite-stable (MSS) tumors comprise ~95% of metastatic colorectal cancer cases and exhibit intrin...

Patient-level OS prediction in NSCLC combining real-world data and published trial results.

Aaron Smith, Luis Olmos, Frank Fuller et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20526

e20526 Background: The majority of early-phase clinical trials in oncology are single-arm trials. External comparator arms...

Explainable machine learning for continuous transcriptomic modeling of metastatic risk in prostate cancer (MET-score).

Sonia Macia, Ruben Lopez Aladid, Rebeca Tovar et al. Jun 01, 2026 pp. 5129-5129 10.1200/jco.2026.44.16_suppl.5129

5129 Background: Metastatic progression is the leading cause of mortality in prostate cancer, yet clinicopathological stra...

An innovative team approach to improve SCLC care across an integrated health system.

Melinda Laine Hsu, Fangzhou Liu, Carley Mitchell et al. Jun 01, 2026 pp. 8111-8111 10.1200/jco.2026.44.16_suppl.8111

8111 Background: Small cell lung cancer (SCLC) is a highly aggressive cancer, with improved overall survival due to recent...

Pathologic treatment effect and first recurrence behavior after curative liver surgery for HCC.

Hassaan Abbasi, Jacob Daniel Hallesy, Yonatan Kaplan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16287

e16287 Background: Locoregional therapy (LRT) is frequently used before curative-intent liver resection or transplantation...

County-level residential radon exposure, testing patterns, and cancer incidence in Michigan.

Kaitlin Driesse-Keegan, Niket Shah, Sai Sushrutha Mudupula Vemula et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22542

e22542 Background: Radon is a well-established lung carcinogen and the second leading cause of lung cancer in the United S...

Childcare provision during breast cancer radiation therapy: Piloting of the Waiting Room Watchers program through the Navigator-Assisted Hypofractionation (NAVAH) program.

Sherri White, J'nay Blackwell, Tanya Hodge et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23113

e23113 Background: Childcare responsibilities remain a major barrier to treatment adherence among women undergoing cancer...

Developing workshops to enhance self-efficacy among patients in cancer survivorship: A collaborative partnership between physiatry and a community cancer support network.

Anh-Dao Tran, Naomi Kaplan, Lauren Kim et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13786

e13786 Background: Cancer survivors face physical, emotional and psychosocial challenges after treatment. There is evidenc...

Phase 1/2a study of concomitant radiotherapy with olaparib and temozolomide in unresectable high-grade glioma patients: Final results from the phase 2a step (OLA-TMZ-RTE-01).

Dinu Stefan, Justine Lequesne, Pierre Kubicek et al. Jun 01, 2026 pp. 2005-2005 10.1200/jco.2026.44.16_suppl.2005

2005 Background: Although the Stupp protocol (radiotherapy + temozolomide (TMZ)) remains the cornerstone of glioblastoma (...

Site and extent of distant metastasis at diagnosis as used to stratify survival in head and neck cancer: A population-based analysis.

Alifya Lokhandwala, Filip J. Sadurski, Malaika Khalid et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18041

e18041 Background: Distant metastases in head and neck cancer (HNC) are associated with poor prognosis. Population-level d...

Geographic disparities in availability of advanced therapies for myeloma from rural-urban access limitations: A population-based registry analysis.

Mridula Preetham Talari, Chelsie Mackanos, Ankita Aggarwal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13511

e13511 Background: Autologous stem cell transplantation (ASCT) remains standard consolidation therapy for transplant-eligi...

Association of patient-reported stress and depression symptoms with ER-specific tumor transcriptional signatures in breast cancer (BC).

Shipra Gandhi, Sayeeda Yasmeen, Spencer Rosario et al. Jun 01, 2026 pp. 565-565 10.1200/jco.2026.44.16_suppl.565

565 Background: Psychological distress is common among women with BC, yet tumor-level biological correlates remain poorly...

Evaluating and validating immune effector dysfunction as a biomarker in bladder cancer.

Houssein Safa, Rasoul Pourebrahim, Meenakshi Anurag et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16601

e16601 Background: Checkpoint inhibitors (CPI) have transformed bladder cancer treatment, yet response rates remain limite...

Pollution and progression: Air quality and stage of lung cancer diagnosis across the U.S.

Raheem Bell, Peter Graffy, Sanjhai Ramdeen et al. Jun 01, 2026 pp. 8003-8003 10.1200/jco.2026.44.16_suppl.8003

8003 Background: Air pollution contributes to increased lung cancer incidence, but whether it accelerates tumor progressio...

Mortality trends from malnutrition and gastrointestinal cancer in US adults: A retrospective analysis.

Mahmoud Tablawy, Alyaa Ahmed Ibrahim, Amro Ali et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15675

e15675 Background: Gastrointestinal cancer is the significant public health issue worldwide, contributing to a substantial...

Intrathecal (IT) therapy–associated pseudoprogression (PsP) in leptomeningeal metastases (LM) from solid tumors.

Zhenyu Pan, Guozi Yang, Yushan Huang et al. Jun 01, 2026 pp. 2037-2037 10.1200/jco.2026.44.16_suppl.2037

2037 Background: Intracranial PsP following systemic immunotherapy has been recognized. IT therapy is a cornerstone of LM...

Association between T-cell LAG-3 expression and clinical benefit in patients with type 2 diabetes and metastatic melanoma treated with immune checkpoint inhibitors.

Sabrina Bruno, Abbe Pannucci, Emma Kozuch et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14578

e14578 Background: Anti-PD-1/anti-LAG-3 combination checkpoint inhibitors, such as nivolumab/relatlimab (nivo/rela), show...

Real-world analysis of eribulin sequencing and outcomes in advanced breast cancer: An LMIC cohort study focusing on line of therapy and prior cyclin-dependent kinase 4/6 inhibitor exposure.

Amit Kichloo, Prithak Madan, Abhinav Bhardwaj et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13050

e13050 Background: In Low-and-Middle-Income Countries (LMICs), eribulin is often a late-line salvage. With increasing use...

Cachexia as an inpatient vulnerability phenotype in lung cancer: A National Inpatient analysis.

Daniel Thomas Jones, Rishi Kumar Nanda, Kyaw Zin Thein et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23225

e23225 Background: Cancer cachexia is a multisystem metabolic syndrome characterized by involuntary tissue catabolism and...

Five-year overall survival in lung adenocarcinoma: Real-world results from three French nationwide cohorts (2000–2010–2020).

Didier Debieuvre, Federico Di Meglio, Le Garff Gwenaelle et al. Jun 01, 2026 pp. 8600-8600 10.1200/jco.2026.44.16_suppl.8600

8600 Background: Long-term (5-year) real-world overall survival (OS) in non–small cell lung cancer (NSCLC) remains poorly...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page